Establishment Labs Holdings Inc.
ESTAEstablishment Labs Holdings Inc. is a medical device company that specializes in the development and commercialization of aesthetic and reconstructive breast implants. Founded in 2014 and based in Costa Rica, the company focuses on innovative silicone gel-filled implants designed for safety, comfort, and natural aesthetic outcomes. Its offerings include the Motiva implant line, which features advancements in biocompatibility and implant durability.
Company News
The global breast implants market is projected to grow from USD 2.93 billion in 2025 to USD 5.62 billion by 2034, driven by rising breast cancer cases and aesthetic surgery demand, with North America leading market share and Asia Pacific expected to witness fastest growth.
The global cosmetic surgery market is expected to grow from $67.2 billion in 2023 to $207.6 billion by 2033, at a CAGR of 11.7%. The market is driven by the growing acceptability and desire for less invasive treatments, with surgical procedures and the female segment holding the highest market share.
Establishment Labs CEO Juan Jose Chacon Quiros sold over $300,000 worth of company stock under a pre-arranged trading plan. The company has seen recent developments, including an expected FDA clearance for its Motiva implants and revenue growth, but also faces challenges with profitability.
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
5 analysts have expressed a variety of opinions on Establishment Labs Hldgs (NASDAQ:ESTA) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bulli...
